Bispecific aC1s-TfR Binding Proteins for BBB Brain Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing therapies targeting the classical complement pathway face challenges in crossing the blood-brain barrier (BBB) for treating neurological disorders, and there is a need for effective aC1s-targeting therapies that can be delivered to the brain.
Innovation Solution
Development of aC1s-binding proteins with specific variable regions and light chain domains that can bind to aC1s, combined with TfR-binding proteins to facilitate transport across the BBB, using bispecific binding proteins that include anti-aC1s and anti-TfR domains.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If therapeutic agents are designed to inhibit aC1s in the brain, then complement-mediated neurological disorders can be treated, but the agents face difficulty in crossing the blood-brain barrier
Solution Approach 1:
The patent uses TfR-binding proteins as intermediary shuttles that exploit the transferrin receptor-mediated transcytosis pathway to transport aC1s-inhibiting therapeutic agents across the blood-brain barrier. The TfR acts as a mediator that facilitates the passage of large molecule drugs from the blood into the brain without compromising the therapeutic agent's inhibitory function.
2Reliability
If the classical complement pathway is inhibited to treat neurological disorders, then complement activation is reduced, but therapeutic agents cannot effectively reach the target site in the brain
Solution Approach 1:
The patent extracts and utilizes the natural BBB transport mechanism mediated by TfR, separating the drug delivery function from the therapeutic mechanism. By hijacking the endogenous transferrin transcytosis pathway, the system bypasses the BBB barrier without interfering with the complement inhibition mechanism once the agent reaches the brain.
3Manufacturing precision
If large molecule drugs are used to target aC1s, then specific complement pathway inhibition is achieved, but transport across the BBB is limited
Solution Approach 1:
The patent merges the aC1s-inhibiting therapeutic agent with a TfR-binding domain to create a bispecific protein that combines both BBB-penetration capability and specific complement pathway inhibition. This fusion allows the large molecule drug to exploit the TfR transport pathway while maintaining its target-specific therapeutic function.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bispecific binding proteins effectively inhibit complement activation in the brain, achieving higher concentrations and inhibiting neuronal complement deposition, thereby treating neurological disorders like ALS, Alzheimer's disease, and other complement-mediated conditions.
Implementation Method 1
TfR imports iron through receptor-mediated endocytosis of transferrin, an iron-binding protein. Since TfR is highly expressed by brain capillary endothelial cells forming the blood-brain barrier (BBB) and transports iron across the BBB through transcytosis
Data Source
AI summary
The present disclosure provides binding proteins that target activated C1s (aC1s), as well as bispecific binding proteins that target aC1s and a central nervous system protein (e.g., transferrin receptor 1). Also provided is the use of these binding proteins to treat neurological complement-mediated disorders.